Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study

Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study PR Newswire OXFORD, England, July 23, 2012 OXFORD, England, July 23, 2012 /PRNewswire/ -- -- Award of US$125,000 will support a second clinical site in Paris, France -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI). The FFB was an early funding collaborator of Oxford BioMedica's pre-clinical ocular programmes and this award furthers the Company's long-standing relationships with FFB and FFBCRI. The award will support the opening of a second clinical ®site in Paris, France for the ongoing UshStat Phase I/IIa study, currently underway in the US. ®UshStat is a novel gene-based treatment for Usher syndrome type 1B, designed and developed by Oxford BioMedica using its proprietary ®LentiVector platform technology, and is the third ocular product to enter clinical development under the Company's collaboration with Sanofi (EURONEXT: SAN and NYSE: SNY).